Research Paper Volume 5, Issue 3 pp 155—173

Figure 3. Determination of PK-resistant PrP^Sc with the 1E4 antibody. A: Brain homogenates from non-CJD, fCJD^Ins+sPrPSc (case 6), VPSPr with 129VV, sCJD type 1, sCJD type 2, and fCJD^Ins+rPrPSc were treated with a variety of concentrations of PK prior to SDS-PAGE and Western blotting with 3F4. PK-resistant PrP was only detected in sCJD type 1, type 2, or fCJD^Ins+rPrP but not in other cases. B: The PK-treated PrP from these cases were detected with 1E4. In contrast, PK-resistant PrP was also detected in both fCJD^Ins+sPrPSc and VPSPr, in addition to sCJD type 1, type 2, and fCJD^Ins+rPrPSc. However, the PK-resistant PrP in fCJD^Ins+sPrPSc was only detected when treated with lower amounts of PK less than 25 μg/ml.